BioCardia Completes Follow-Up Visit in CardiAMP HF Clinical Trial – 8-K Filing Reveals

BioCardia, Inc., a Delaware-based company listed on the Nasdaq Capital Market under the symbol BCDA, announced through an 8-K filing on October 28, 2024, the conclusion of its final protocol-specified follow-up visit in the CardiAMP HF trial. The trial, which is a prospective, randomized double-blinded study, is placebo-procedure controlled and spans multiple centers.

The company published a press release on the same day, detailing the completion of this significant phase within the CardiAMP HF pivotal clinical trial. The trial’s progress marks a crucial milestone for BioCardia as it advances in its research and development efforts.

This update comes in the wake of BioCardia’s persistent endeavors in the field of cardiovascular therapies. The attached Exhibit 99.1 of the filing includes the full press release for further insights into this development.

Accompanying the announcement in the filing is Exhibit 104, which presents the Cover Page Interactive Data File in an Inline XBRL Document format.

BioCardia’s focus on advancing therapies for cardiovascular conditions remains at the forefront of its operations. The completion of the last protocol-specified follow-up visit in the CardiAMP HF trial underscores the company’s commitment to clinical excellence and innovation in the medical field. Investors and stakeholders keen on the latest developments in BioCardia’s clinical trials can refer to the attached press release for comprehensive details.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioCardia’s 8K filing here.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.